Company profilePharmaceutical#610 of 1,318 in Pakistan✓ No DRAP alerts

Arreta Pharmaceuticals (Pvt.) Ltd. DML: 000846

Pharmaceutical company · 18 brands · 39 molecules

Ranked #191 of 213 companies in Other Beta-Lactam, Cephalosporins & Penems

18 registered products 16 pharmaceutical brands 39 distinct molecules 0 DRAP alerts

Company overview

18
registered products
16
pharmaceutical brands
39
distinct molecules
2
therapeutic classes
0
DRAP alerts

Arreta Pharmaceuticals (Pvt.) Ltd. DML: 000846 is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 18 product registrations across 39 distinct molecules. Its portfolio is concentrated in Other Beta-Lactam, Cephalosporins & Penems and Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord). It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Cephalexin2 brands
Cefixime2 brands
Phenobarbitone ...... 30 Mg1 brand
Letrozole ...... 2.5 Mg1 brand
Letrozole1 brand
Clarithromycin ...... 500 Mg1 brand
Clarithromycin ...... 250 Mg1 brand
Loperamide ...... 2 Mg1 brand
Folic Acid1 brand

Therapeutic classes

Other Beta-Lactam, Cephalosporins & Penems · 1Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official25 products · Rs 53.7 – Rs 6,948.69
Median across source: Rs 306.03

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for Arreta

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.